Dengue Fever (DF) is a mosquito-borne disease (Aedes) caused by single strand RNA viruses of the family flaviviridae. It is is currently the second most common specific etiologic diagnosis among returned travelers with febrile illness after malaria globally.
It is the most common febrile illness among travelers returning from Southeast Asia and South Central Asia.
The disease not only poses a risk to the health of the individual traveler but is also a public health problem as returning viraemic travelers contribute to the spread of the disease. Dengue importation into vector infected areas has caused large numbers of autochthonous cases in the EU, notably 2000 cases in Madeira, Portugal 2012-13.
Increasing trends and attack rates of dengue infection seen in travelers would justify the need for a dengue vaccine in this target group. The 3 dose (0, 6 & 12 mos) Sanofi Pasteur vaccine (CYD-TDV, Dengvaxia) has been licensed since 2015 for the prevention of disease caused by all four dengue virus serotypes in preadolescents, adolescents and adults, 9 to 45 years of age living in endemic areas. However, it has several drawbacks as a travel vaccine, mainly its long administration schedule.
This MarketVIEW product consists of a detailed Executive presentation (~80 slides) and comprehensive MS-Excel work books which forecast the potential commercial value of dengue fever vaccine(s) by competitor in travelers to 2030 from major Western points of origin to 85 countries with ongoing transmission. The model(s) contain value ($ m) and volume (mio doses) predictions in different types of traveler e.g. Vacation and Visiting Friends/Family and Business + Other in both first time and repeat/experienced individuals per region*.
Detailed discussion is provided with regard to the comparative suitability of Dengvaxia, DenVAX (TAK-003), TetraVAX and TDENV-PIV to serve the travelers segment and respective product forecasts are included to 2030.